News
BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...
The autoimmune disorder systemic lupus erythematosus (SLE) involves upregulation of IgD, and studies have shown that anti-IgD antibodies can alleviate the autoimmune disorder rheumatoid arthritis in ...
AbbVie released positive topline data from its phase 3 UP-AA trial demonstrating safety and efficacy for upadacitinib for ...
The use of hydroxychloroquine in patients with lupus nephritis is linked to kidney function benefits, especially in those with chronic kidney disease stage ≥ 3.
A recent dual-cohort study has found that Lupus Low Disease Activity State (LLDAS) is an attainable and effective treatment ...
Identifying early predictors of chronic kidney disease (CKD) progression in patients with lupus nephritis may help define a high-risk group.
Lupus Foundation of America and Lupus Canada award research grant to study aiming to uncover the causes of fatigue in people with lupus: Washington, DC Monday, July 28, 2025, 10:0 ...
A new study found an association between hydroxychloroquine (HCQ) use and early and long-term benefits on kidney function in ...
Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets ...
DelveInsight's CD40/CD40L Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results